At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 261 enrolled
Drug / intervention
rimegepant 75 mg ODT +1 moredrug
Likely dose
rimegepant 75 mg ODTfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Chronic Rhinosinusitis (CRS) With or Without Nasal Polyps
In Brief
A Phase 3 clinical trial evaluating rimegepant 75 mg ODT and Matching placebo for Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps. Completed, enrolled 261 participants across 33 sites.
Detailed Summary
The purpose of this study is to compare the efficacy and safety of rimegepant versus placebo in the acute treatment of chronic rhinosinusitis (CRS) with and without nasal polyps.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
Enrollment StartFeb 2022
First PostedFeb 2022
Primary CompletionMar 2024
Study CompletionApr 2024
TodayJul 2026
First PostedFeb 21, 2022
Enrollment StartFeb 17, 2022
Primary CompletionMar 11, 2024
Study CompletionApr 2, 2024
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 4.4 years ago
Interventions
rimegepant 75 mg ODTdrug
One dose of rimegepant 75 mg ODT
Matching placebodrug
One dose of matching placebo